Accreditation Statement and Credit Designation

European Accreditation Council for Continuing Medical Education (UEMS/EACCME)

An application has been made to the UEMS-EACCME® for CME accreditation for this event. 

The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.

American Medical Association (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-union-medical-specialties-uems.

Royal College of Physicians and Surgeons of Canada

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit www.royalcollege.ca/rcsite/cpd/providers/international-accreditation-agreements-e.

Educational Objectives 

After participating in this educational event, learners should be able to:

• Integrate newly acquired knowledge into their Continuous Professional Development (CPD) plan, addressing individual learning needs.
• Evaluate the pathophysiological links between autoimmune hematology, immunodeficiencies, and malignancies to enhance integrated diagnostic and treatment strategies.
• Analyze the diagnostic approaches in hematology, immunology, and histopathology for complex immunodeficiency-related lymphoproliferative disorders.
• Identify the genetic and somatic factors contributing to genetically determined cytopenia and bone marrow failure syndromes to improve patient diagnosis and management.
• Apply knowledge of monogenic syndromes in hematopoiesis to deepen understanding of hematologic malignancies and disorders.
• Compare the different treatment strategies for hematological alloimmunity, including approaches in allogeneic HSCT, platelet alloimmunity, and neonatal hematology.
• Assess the role of immune deficiencies in predisposing individuals to malignancy and understand new genes and mechanisms involved in cancer predisposition.
• Discuss the management of secondary immune disorders (SID) in patients undergoing CAR T cell therapy, and explore treatment options beyond CAR T.
• Develop an understanding of treatment protocols for malignancies in immunocompromised patients, including children with PID and patients with AT, to improve therapeutic decision-making.

Target Audience   

The principal intended recipients of the ESID-EHA-SIOPE Focused Symposium 2025 are fully qualified medical specialists within the fields of Immunology, Hematology, and Oncology, specifically those with advanced expertise in the clinical management and research of immunodeficiencies, hematologic disorders, and oncologic conditions. This includes senior specialists, consultants, and clinicians who are engaged in the diagnosis and treatment of complex patient cases. Additionally, the event is designed for fellows, junior faculty, and researchers who are actively contributing to the development of new insights and treatments within these fields. The symposium aims to address the educational needs of experienced professionals and emerging experts, providing them with the latest research and advancements in these multidisciplinary specialties.

To Receive Your CME/CPD Certificate   

The CME/CPD certificate will be available after completing the online evaluation and credit-claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

• Kindly note that the INTER 2025 online evaluation will be active on the last day of the meeting. You will then be able to access it and claim your CME/CPD certificate. 

Disclosure and Resolution of Personal Conflicts of Interest  

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest are resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

• Disclosure information will be available here at least one week prior to the event. 

Industry Support Disclosure  

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organisations is made in the programme guide, on the event website, and with signage during the event.  

• View a list of all industry supporters here.

• View detailed programmes for all Industry Sessions here.

Commitment to the Highest Standards in CME/CPD

Kenes is committed to being a valuable and knowledgeable partner in the design and delivery of educationally strong, independent, transparent, and effective CME/CPD programmes. Kenes is a proud member of the Good CME Practice Group (gCMEp), a member organisation contributing to improving health outcomes by:

Championing best practice in CME/CPD Maintaining and improving standards Mentoring and educating Working in collaboration with critical stakeholders

Membership in the Good CME Practice Group illustrates Kenes commitment to high standards and knowledgeable partnership with its clients in the design and delivery of medical events.